Jomha Aliya, Sohn Myren N, Watson Molly, Kopala-Sibley Daniel C, McGirr Alexander
Department of Psychology, Mount Royal University, Calgary, Alberta, Canada; Department of Psychiatry, University of Calgary, Calgary, Alberta, Canada; Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada; Mathison Centre for Mental Health Research and Education, Calgary, Alberta, Canada.
Department of Psychiatry, University of Calgary, Calgary, Alberta, Canada; Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada; Mathison Centre for Mental Health Research and Education, Calgary, Alberta, Canada.
J Affect Disord. 2025 Mar 1;372:210-215. doi: 10.1016/j.jad.2024.12.006. Epub 2024 Dec 3.
Self-criticism is a risk factor for depression and depressive symptom persistence, however higher degrees of self-criticism have been associated with greater antidepressant benefits from repetitive transcranial magnetic stimulation (rTMS), suggesting that self-criticism may act as a proxy for function of the targeted circuit. We test this hypothesis using secondary data from an rTMS treatment trial where an NMDA receptor agonist (D-Cycloserine) was used to enhance TMS synaptic plasticity to improve efficacy. We hypothesized that self-criticism would be more strongly associated with treatment outcome when stimulation was paired with D-Cycloserine than with a placebo.
In a 4-week single-site double-blind randomized placebo-controlled trial, fifty adults with Major Depressive Disorder (MDD) (NCT03937596) were randomized to receive placebo or D-Cycloserine (100 mg) with daily intermittent theta-burst stimulation (iTBS) to the left dorsolateral prefrontal cortex (DLPFC). At baseline and after treatment, self-criticism was assessed using the Depressive Experiences Questionnaire as a secondary trial outcome and depressive symptoms were assessed using the clinician rated Montgomery Asberg Depression Rating scale (MADRS). Clinical response was defined as a ≥50 % decrease on the MADRS.
Self-criticism differentially predicted antidepressant effects when operationalized as both percent decrease on the MADRS and clinical response (≥50 % decrease), with a statistically significantly stronger association in the iTBS+D-Cycloserine group than the iTBS+Placebo condition. Self-criticism did not significantly change in either condition over the course of treatment.
Our data suggests that iTBS to the left DLPFC engages a circuit related to self-criticism. Higher levels of self-criticism predicted better response to iTBS with an adjuvant that enhances synaptic plasticity. This suggests that personality traits may be used to tailor non-invasive neurostimulation treatments.
自我批评是抑郁症及抑郁症状持续存在的一个风险因素,然而,更高程度的自我批评与重复经颅磁刺激(rTMS)带来的更大抗抑郁效果相关,这表明自我批评可能作为目标回路功能的一个替代指标。我们使用一项rTMS治疗试验的二次数据来检验这一假设,该试验中使用了一种N-甲基-D-天冬氨酸受体激动剂(D-环丝氨酸)来增强TMS突触可塑性以提高疗效。我们假设,当刺激与D-环丝氨酸联合使用时,自我批评与治疗结果的关联会比与安慰剂联合使用时更强。
在一项为期4周的单中心双盲随机安慰剂对照试验中,50名患有重度抑郁症(MDD)的成年人(NCT03937596)被随机分配接受安慰剂或D-环丝氨酸(100毫克),并对左侧背外侧前额叶皮质(DLPFC)进行每日间歇性theta波爆发刺激(iTBS)。在基线和治疗后,使用抑郁体验问卷评估自我批评作为次要试验结果,使用临床医生评定的蒙哥马利-阿斯伯格抑郁评定量表(MADRS)评估抑郁症状。临床反应定义为MADRS评分降低≥50%。
当将自我批评作为MADRS评分降低百分比和临床反应(降低≥50%)来衡量时,其对抗抑郁效果的预测存在差异,在iTBS+D-环丝氨酸组中,其关联在统计学上显著强于iTBS+安慰剂组。在治疗过程中,两种情况下的自我批评均无显著变化。
我们的数据表明,对左侧DLPFC进行iTBS会激活一个与自我批评相关的回路。更高水平的自我批评预示着对增强突触可塑性的辅助性iTBS反应更好。这表明人格特质可用于定制非侵入性神经刺激治疗。